Spherium

Spherium Biomed is a clinical-stage biotechnology company based in Barcelona, Spain, that specializes in the development of innovative biomedical therapies. Founded in 2013 as a joint venture between the pharmaceutical group Ferrer and the management team of Janus Developments, the company focuses on bridging the gap between academic research and industrial drug development. Its lead candidate, Mucomel, is a melatonin-based formulation designed to prevent and treat oral mucositis in cancer patients undergoing radiotherapy and chemotherapy. Spherium's portfolio also includes programs for acute kidney injury and muscle regeneration, utilizing an asset-centric business model to de-risk early-stage innovations. The company leverages its expertise in regulatory affairs and clinical trials to advance projects through clinical proof-of-concept for further licensing or partnership.